EPARs - Avonex/interferon beta-1a

FICHA FARMACOLÓGICA de interferon beta-1a. Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. Marzo 20, 2009.

abrir aquí:
EPARs for authorised medicinal products for human use - Avonex

Active Substance
interferon beta-1a
International Nonproprietary Name or Common Name
Interferon beta-1a
Pharmaco-therapeutic Group
Interferons
ATC Code
L03AB07


Therapeutic Indication:
Avonex is indicated for the treatment of

- Patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; Avonex slows the progression of disability and decreases the frequency of relapses.

- Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.

Avonex should be discontinued in patients who develop progressive MS.

Date of issue of Marketing Authorisation valid throughout the European Union
13 March 1997